WSB1

Summary

WSB1 (WD repeat and SOCS box containing 1, HGNC:19221) is a protein-coding gene on chromosome 17q11.1, encoding WD repeat and SOCS box-containing protein 1 (Q9Y6I7). Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

This gene encodes a member of the WD-protein subfamily. This protein shares a high sequence identity to mouse and chick proteins. It contains several WD-repeats spanning most of the protein and an SOCS box in the C-terminus. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.

Source: NCBI Gene 26118 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 77 total
• MANE Select transcript: NM_015626

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19221
Approved symbol	WSB1
Name	WD repeat and SOCS box containing 1
Location	17q11.1
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp564A122, DKFZp564B0482, SWIP1
Ensembl gene	ENSG00000109046
Ensembl biotype	protein_coding
OMIM	610091
Entrez	26118

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 16 protein_coding, 5 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000262394, ENST00000348811, ENST00000427287, ENST00000467843, ENST00000487603, ENST00000578312, ENST00000579733, ENST00000581089, ENST00000581185, ENST00000581440, ENST00000582208, ENST00000583096, ENST00000583193, ENST00000583742, ENST00000583786, ENST00000584114, ENST00000584354, ENST00000866202, ENST00000866203, ENST00000866204, ENST00000922556, ENST00000922557, ENST00000964189, ENST00000964190

RefSeq mRNA: 3 — MANE Select: NM_015626 NM_001348350, NM_015626, NM_134265

CCDS: CCDS11220, CCDS11221

Canonical transcript exons

ENST00000262394 — 9 exons

Exon	Start	End
ENSE00003482915	27303367	27303635
ENSE00003499511	27301788	27301956
ENSE00003533529	27312210	27315926
ENSE00003582508	27306782	27306882
ENSE00003602323	27294114	27294435
ENSE00003622356	27304780	27304911
ENSE00003663959	27311509	27311616
ENSE00003671471	27309100	27309272
ENSE00003680824	27310061	27310174

Expression profiles

Bgee: expression breadth ubiquitous, 303 present calls, max score 99.27.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 131.1580 / max 1769.5256, expressed in 1827 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159951	130.5197	1827
159956	0.6383	299

Top tissues by expression

303 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus callosum	UBERON:0002336	99.27	gold quality
mucosa of stomach	UBERON:0001199	99.18	gold quality
lower lobe of lung	UBERON:0008949	99.15	gold quality
blood vessel layer	UBERON:0004797	99.13	gold quality
inferior vagus X ganglion	UBERON:0005363	99.10	gold quality
tibial nerve	UBERON:0001323	98.95	gold quality
popliteal artery	UBERON:0002250	98.91	gold quality
CA1 field of hippocampus	UBERON:0003881	98.91	gold quality
tibial artery	UBERON:0007610	98.91	gold quality
endocervix	UBERON:0000458	98.90	gold quality
endothelial cell	CL:0000115	98.89	gold quality
left uterine tube	UBERON:0001303	98.84	gold quality
artery	UBERON:0001637	98.84	gold quality
upper lobe of lung	UBERON:0008948	98.84	gold quality
subthalamic nucleus	UBERON:0001906	98.80	gold quality
upper lobe of left lung	UBERON:0008952	98.80	gold quality
body of uterus	UBERON:0009853	98.80	gold quality
right coronary artery	UBERON:0001625	98.75	gold quality
left ovary	UBERON:0002119	98.74	gold quality
cauda epididymis	UBERON:0004360	98.73	gold quality
renal medulla	UBERON:0000362	98.71	gold quality
visceral pleura	UBERON:0002401	98.70	gold quality
right lung	UBERON:0002167	98.69	gold quality
aorta	UBERON:0000947	98.65	gold quality
right ovary	UBERON:0002118	98.63	gold quality
spleen	UBERON:0002106	98.62	gold quality
gall bladder	UBERON:0002110	98.62	gold quality
trabecular bone tissue	UBERON:0002483	98.62	gold quality
descending thoracic aorta	UBERON:0002345	98.61	gold quality
medulla oblongata	UBERON:0001896	98.60	gold quality

Single-cell (SCXA)

Detected in 12 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	1930.87
E-HCAD-1	yes	74.86
E-MTAB-8410	yes	18.89
E-CURD-46	yes	12.57
E-GEOD-130148	yes	10.24
E-CURD-112	yes	9.20
E-CURD-135	no	3254.58
E-GEOD-81608	no	1669.10
E-GEOD-131882	no	1659.50
E-MTAB-6108	no	1035.29
E-HCAD-31	no	2.03
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HIF1A

miRNA regulators (miRDB)

94 targeting WSB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872

Literature-anchored findings (GeneRIF, showing 15)

• WSB-1 is part of an E3 ubiquitin ligase for the thyroid-hormone-activating type 2 iodothyronine deiodinase (D2). (PMID:15965468)
• WSB1 shows strong correlations between expression level and copy number, and also enhances the prognostic prediction when combined with other current prognostic factors in neuroblastoma. (PMID:16804916)
• the regulatory mechanisms by which HIPK2 is maintained at a low level, by WSB-1 in cells under normal conditions, and stabilized by genotoxic stresses. (PMID:18093972)
• Data on WSB1 regulation support the hypothesis that activation of stress-response mechanisms helps cancer cells establishing metastases and suggest relevance to cancer development of other genes overexpressed in xenografts (PMID:18575577)
• HIF1 has a role in regulating WSB-1 expression, which promotes hypoxia-induced chemoresistance in hepatocellular carcinoma cells (PMID:23792163)
• combination of WSB1(3) silencing together with WSB1 isoforms 1+2 silencing in NB cells showed reduced growth, enhanced apoptosis rate, and increased sensitivity to chemotherapeutic agents, specifically related to low expression of WSB1 (PMID:24441107)
• WSB1 up-regulates the expression of HIF-1alpha’s target genes and promotes cancer invasion and metastasis through its effect on pVHL (PMID:26545811)
• howed that miR-592 directly binds to the 3’-UTR of the WSB1 gene, thus disrupting hypoxia inducible factor-1alpha (HIF-1alpha) protein stabilization (PMID:27153552)
• WSB1 in glucose metabolism, and perhaps in mediating the Warburg effect in cancer cells by maintaining the function of HIF1. (PMID:27542736)
• WSB1 is one of the key players of early oncogenic events through ATM degradation and destruction of the tumorigenesis barrier. (PMID:27958289)
• WSB-1 may be an important regulator of aggressive metastatic disease in hormone receptor-negative breast cancer. WSB-1 could therefore represent a novel regulator and therapeutic target for secondary breast cancer in these patients. (PMID:29540773)
• High expression of WSB1 is associated with poor prognosis in hepatocellular carcinoma and affects epithelial-mesenchymal transition. (PMID:33099929)
• WSB1 and IL21R Genetic Variants Are Involved in Th2 Immune Responses to Ascaris lumbricoides. (PMID:33692795)
• WSB1 Involvement in Prostate Cancer Progression. (PMID:37628609)
• WSB1/2 target chromatin-bound lysine-methylated RelA for proteasomal degradation and NF-kappaB termination. (PMID:38452206)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	wsb1	ENSDARG00000021343
mus_musculus	Wsb1	ENSMUSG00000017677
rattus_norvegicus	Wsb1	ENSRNOG00000012929

Paralogs (1): WSB2 (ENSG00000176871)

Protein

Protein identifiers

WD repeat and SOCS box-containing protein 1 — Q9Y6I7 (reviewed: Q9Y6I7)

Alternative names: SOCS box-containing WD protein SWiP-1

All UniProt accessions (9): Q9Y6I7, B4DGB8, B4DTL1, J3KRG6, J3KS88, J3KSQ3, J3KT03, J3KTB3, J3QLM8

UniProt curated annotations — full annotation on UniProt →

Function. Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes type II iodothyronine deiodinase/DIO2. Confers constitutive instability to HIPK2 through proteasomal degradation.

Subunit / interactions. Interacts with DIO2. Component of the probable ECS(WSB1) E3 ubiquitin ligase complex which contains CUL5, RNF7/RBX2, Elongin BC complex and WSB1. Component of a probable ECS-like E3 ubiquitin-protein ligase complex which contains CUL5, RBX1, Elongin BC complex and WSB1. Interacts with CUL5, RNF7, ELOB and ELOC. Binds to HIPK2 through WD40 repeats.

Domain organisation. The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.

Pathway. Protein modification; protein ubiquitination.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9Y6I7-1	1	yes
Q9Y6I7-2	2
Q9Y6I7-3	3
Q9Y6I7-4	4

RefSeq proteins (3): NP_001335279, NP_056441, NP_599027 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001496	SOCS_box	Domain
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR020472	WD40_PAC1	Repeat
IPR036036	SOCS_box-like_dom_sf	Homologous_superfamily
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR051983	WSB_SOCS-box_domain	Family

Pfam: PF00400, PF07525

UniProt features (19 total): repeat 6, splice variant 5, sequence conflict 5, chain 1, sequence variant 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y6I7-F1	84.61	0.62

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 254 (showing top): AHRARNT_01, GCACCTT_MIR18A_MIR18B, MODULE_97, GCM_MAP4K4, BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN, AAGCAAT_MIR137, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, MODULE_182, BONCI_TARGETS_OF_MIR15A_AND_MIR16_1, chr17q11, GTGCCTT_MIR506, ONKEN_UVEAL_MELANOMA_UP

GO Biological Process (5): protein polyubiquitination (GO:0000209), intracellular signal transduction (GO:0035556), protein K27-linked ubiquitination (GO:0044314), protein aggregate center assembly (GO:0140454), protein ubiquitination (GO:0016567)

GO Molecular Function (2): ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), Lewy body (GO:0097413), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	2
cellular anatomical structure	2
protein ubiquitination	1
signal transduction	1
protein polyubiquitination	1
cellular component assembly	1
protein modification by small protein conjugation	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
cytoplasm	1
inclusion body	1

Protein interactions and networks

STRING

1826 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WSB1	CUL5	Q93034	818
WSB1	RBX1	P62877	797
WSB1	CTCF	P49711	781
WSB1	NF1	P21359	721
WSB1	IGF2	P01344	693
WSB1	HIPK2	Q9H2X6	667
WSB1	USP33	Q8TEY7	666
WSB1	CISH	Q9NSE2	646
WSB1	ELOB	Q15370	633
WSB1	CTCFL	Q8NI51	629
WSB1	DIO2	Q92813	605
WSB1	USP20	Q9Y2K6	593
WSB1	ELOC	Q15369	576
WSB1	COX7A1	P24310	560
WSB1	MNT	Q99583	548

IntAct

28 interactions, top by confidence:

A	B	Type	Score
CUL5	SOCS2	psi-mi:“MI:0914”(association)	0.880
CUL5	SOCS6	psi-mi:“MI:0914”(association)	0.640
CUL5	SOCS7	psi-mi:“MI:0914”(association)	0.640
WSB1	VHL	psi-mi:“MI:0915”(physical association)	0.560
LRRK2	WSB1	psi-mi:“MI:0915”(physical association)	0.540
WSB1	LRRK2	psi-mi:“MI:0403”(colocalization)	0.540
RNF7	SOCS7	psi-mi:“MI:0914”(association)	0.530
WSB1	Hipk2	psi-mi:“MI:0915”(physical association)	0.520
Hipk2	WSB1	psi-mi:“MI:0915”(physical association)	0.520
HIPK2	WSB1	psi-mi:“MI:0915”(physical association)	0.400
GSK3B	WSB1	psi-mi:“MI:0915”(physical association)	0.370
CFTR	SNHG32	psi-mi:“MI:0914”(association)	0.350
DCUN1D1	RGSL1	psi-mi:“MI:0914”(association)	0.350
CUL5	DDX3X	psi-mi:“MI:0914”(association)	0.350
RNF7	SOCS2	psi-mi:“MI:0914”(association)	0.350
ezrA	WSB1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (537): DIO2 (Biochemical Activity), ARHGDIB (Affinity Capture-Western), WSB1 (Affinity Capture-Western), WSB1 (Affinity Capture-MS), WSB1 (Affinity Capture-Western), LRRK2 (Affinity Capture-Western), LRRK2 (Biochemical Activity), UBE2D2 (Reconstituted Complex), WSB1 (Affinity Capture-RNA), WSB1 (Affinity Capture-MS), WSB1 (Proximity Label-MS), WSB1 (Affinity Capture-MS), WSB1 (Affinity Capture-MS), WSB1 (Affinity Capture-MS), WSB1 (Negative Genetic)

ESM2 similar proteins: A0JM23, A0JP70, B2RZ17, E1BVR9, O14727, O54927, O88879, O94952, P0CI65, Q08BB3, Q08DV6, Q13309, Q32KQ2, Q3U3W5, Q3U821, Q3UDP0, Q3UMR0, Q3UR70, Q58D00, Q5R5S1, Q5REW9, Q5XJS5, Q60584, Q68EI0, Q6AX81, Q6AZT7, Q6DFC6, Q6P1V3, Q6P2P2, Q6P2S7, Q6ZMY6, Q7T2F6, Q7TNH6, Q7Z494, Q8BHD1, Q8C5V5, Q8IWA0, Q8NA23, Q8VDH1, Q96NW4

Diamond homologs: A0CH87, A0DB19, A1CF18, A1CUD6, A7S338, A8NEG8, A8XZJ9, A9V790, B0LSW3, B0XM00, B2AEZ5, B2B766, B2VWG7, B3MEY6, B3NPW0, B3S4I5, B4GAJ1, B4HSL3, B4JWA1, B4KT48, B4LQ21, B4MY65, B4P6P9, B4QHG6, B5X3C4, B5X3Z6, B6GZD3, B6HP56, B6QC06, B7FNU7, B7PS00, B8N9H4, B8P4B0, B8PD53, B9WD30, C0NRC6, C0S902, C1GB49, C3XVT5, C4Q0P6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
WSB1	down-regulates	HIPK2	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 16 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neddylation	6	21.9×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	6	26.1×	6e-06
protein ubiquitination	6	20.7×	2e-05
intracellular signal transduction	6	19.1×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1735 predictions. Top by Δscore:

Variant	Effect	Δscore
17:27301957:G:GG	donor_gain	1.0000
17:27304770:T:G	acceptor_gain	1.0000
17:27304772:A:AG	acceptor_gain	1.0000
17:27304773:T:G	acceptor_gain	1.0000
17:27304776:TTAG:T	acceptor_loss	1.0000
17:27304777:TA:T	acceptor_loss	1.0000
17:27304778:A:AC	acceptor_loss	1.0000
17:27304778:A:AG	acceptor_gain	1.0000
17:27304778:AG:A	acceptor_gain	1.0000
17:27304779:G:A	acceptor_loss	1.0000
17:27304779:G:GA	acceptor_gain	1.0000
17:27304779:GG:G	acceptor_gain	1.0000
17:27304779:GGA:G	acceptor_gain	1.0000
17:27304779:GGAA:G	acceptor_gain	1.0000
17:27304779:GGAAA:G	acceptor_gain	1.0000
17:27304908:GATG:G	donor_gain	1.0000
17:27304911:GGTA:G	donor_loss	1.0000
17:27304912:G:GC	donor_loss	1.0000
17:27304912:G:GG	donor_gain	1.0000
17:27304913:T:A	donor_loss	1.0000
17:27306880:GCA:G	donor_gain	1.0000
17:27306883:G:GG	donor_gain	1.0000
17:27308665:G:GT	donor_gain	1.0000
17:27308668:G:GG	donor_gain	1.0000
17:27309093:A:AG	acceptor_gain	1.0000
17:27309093:ATT:A	acceptor_gain	1.0000
17:27309094:T:G	acceptor_gain	1.0000
17:27309094:TTGCA:T	acceptor_loss	1.0000
17:27309095:T:A	acceptor_gain	1.0000
17:27309095:TGCAG:T	acceptor_loss	1.0000

AlphaMissense

2770 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:27304893:T:A	W198R	1.000
17:27304893:T:C	W198R	1.000
17:27301896:C:A	A50D	0.999
17:27303588:C:A	A144D	0.999
17:27303620:T:A	W155R	0.999
17:27303620:T:C	W155R	0.999
17:27304885:T:C	L195P	0.999
17:27304895:G:C	W198C	0.999
17:27304895:G:T	W198C	0.999
17:27306859:T:C	C230R	0.999
17:27309101:T:A	V238D	0.999
17:27309109:T:A	W241R	0.999
17:27309109:T:C	W241R	0.999
17:27309203:C:A	A272D	0.999
17:27310158:A:C	S328R	0.999
17:27310160:C:A	S328R	0.999
17:27310160:C:G	S328R	0.999
17:27303486:T:A	V110D	0.998
17:27303585:T:C	L143P	0.998
17:27303593:G:T	G146W	0.998
17:27304819:T:A	V173D	0.998
17:27304834:T:C	F178S	0.998
17:27304863:T:C	S188P	0.998
17:27304867:C:A	A189D	0.998
17:27304869:T:C	S190P	0.998
17:27304875:G:C	D192H	0.998
17:27304876:A:T	D192V	0.998
17:27304894:G:C	W198S	0.998
17:27306861:T:G	C230W	0.998
17:27306862:T:C	S231P	0.998

dbSNP variants (sampled 300 via entrez): RS1000171764 (17:27312524 ATAT>A), RS1000393546 (17:27305954 T>C), RS1000453720 (17:27312774 T>A), RS1000497727 (17:27313603 T>C), RS1000905554 (17:27301647 C>T), RS1000964794 (17:27307891 C>T), RS1001079151 (17:27296558 A>G), RS1001081718 (17:27307354 ATTGT>A), RS1001509515 (17:27306365 A>C), RS1001559434 (17:27313220 A>C,G), RS1001665217 (17:27313087 T>C), RS1001737204 (17:27301052 A>G), RS1001797178 (17:27306546 A>C), RS1001847860 (17:27308105 A>G), RS1002129416 (17:27308452 T>C)

Disease associations

OMIM: gene MIM:610091 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001063_2	Chronic myeloid leukemia	1.000000e-12
GCST001713_19	Dental caries	7.000000e-07
GCST008362_20	Birth weight	2.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004344	birth weight

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects cotreatment, decreases expression	8
sodium arsenite	increases expression, affects expression, decreases expression	4
Acetaminophen	affects expression, increases expression	3
cobaltous chloride	increases expression, decreases reaction	2
Resveratrol	increases expression, decreases expression, affects cotreatment	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Ethanol	affects cotreatment, increases expression, decreases expression, increases abundance	2
Calcitriol	increases expression, affects cotreatment	2
Tretinoin	increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, decreases expression	2
Particulate Matter	increases expression, affects cotreatment, decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
sodium arsenate	increases abundance, increases expression	1
decabromobiphenyl ether	affects binding, increases reaction	1
beta-lapachone	increases expression	1
arsenite	affects expression	1
zinc chloride	decreases reaction, increases expression	1
linalool	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
torcetrapib	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
eprenetapopt	affects expression, affects reaction	1
NSC 689534	affects binding, increases expression	1
PCI 5002	affects cotreatment, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7HS	Ubigene HEK293T WSB1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.